Sri Lanka has recorded more than 55,000 dengue cases in 2026, with about 1,000 patients in hospital at any time and 29 deaths, according to The BMJ. The government has deployed the military and drones in support of the public-health response. The same Aedes albopictus vector is established in parts of Europe, and mainland France recorded 809 autochthonous chikungunya cases in 2025. This article sets out the case data, the conditions that favour the vector, and the household measures that reduce exposure.
Sri Lanka has recorded more than 55,000 dengue cases this year. About 1,000 patients are in hospital at any one time, and 29 people have died. The BMJ reported those figures on 2 July 2026. The case count rose from about 47,500 to 55,000 in two weeks, and daily hospital admissions have run above 1,000. The government has deployed the military and drones to support the public-health response. The drones carry out surveillance and targeted larvicide application.
For a European reader, the Sri Lankan outbreak is not a forecast of what will arrive at home next week. It is a current example of the transmission that Aedes albopictus can sustain when the conditions that favour it hold across several warm seasons. Sri Lankan diaspora travel runs through EU airports, so the outbreak is close in human terms. The conditions themselves, rising temperatures, container trade and urban water storage, are present in Europe too. Sri Lanka has a population of 22 million, and its health system has recorded more cases than its planning assumed.
What the data shows
- The BMJ reported on 2 July 2026 that Sri Lanka has recorded more than 55,000 dengue cases this year. About 1,000 patients were in hospital at any time, and 29 deaths were attributed to the outbreak. The case count rose from about 47,500 to 55,000 in two weeks.
- The BMJ also documented the military deployment in support of the public-health response. Drones carried out surveillance and targeted larvicide application. Daily hospital admissions ran above 1,000, past the level the country's planning had assumed.
- The European Centre for Disease Prevention and Control and the World Health Organization maintain routine surveillance for autochthonous transmission in EU/EEA countries. The ECDC has recorded no autochthonous dengue or chikungunya cases in the mainland EU this season. Autochthonous means the person was infected locally, not while travelling.
- The IJID Regions paper (PMID 42382010) is the first quantitative cost-of-illness accounting for a single arboviral season in metropolitan France. Its central argument is that the documented figure underestimates the true burden. That finding travels to other non-endemic European countries.
The conditions that favour Aedes albopictus
The presence of soldiers and drones is unfamiliar for a European reader. The public-health situation behind it is not. A country has recorded transmission past the level its planning assumed, and the conditions that produced that situation are not unique to Sri Lanka.
Rising mean temperatures extend the breeding season of Aedes albopictus. Container trade moves its habitat across borders. Urbanisation and irregular water storage build the standing-water reservoir the mosquito needs. These conditions describe the operating environment of the vector across many countries in 2026. The European Centre for Disease Prevention and Control named Paris, Vienna, Zagreb, London and Frankfurt as dengue-risk cities in January.
The agency also records Aedes albopictus advancing northward, with new cities colonised each season. Sri Lanka is therefore not a foreign-news story to read and set aside. It is one country's experience of the conditions that European surveillance is now tracking. The practical question for a public-health system is what to do when the case count climbs past the level its planning assumed.
What the European position is
Europe is not in Sri Lanka's position. The ECDC has recorded no autochthonous dengue or chikungunya cases in the mainland EU this season. The most recent ECDC weekly report confirmed that position. The public-health protection available to a European reader is real and in place.
The picture is still changing. The 2025 autochthonous chikungunya outbreak in mainland France closed on 809 confirmed cases. That outbreak showed that a non-endemic European country can sustain season-scale transmission when the conditions align with a single warm summer. The ECDC records the vector itself advancing across the continent, with new cities colonised each season.
The IJID Regions paper puts a cost on a single arboviral season in metropolitan France for the first time. It follows the 2025 chikungunya outbreak in the same country. The paper argues that the measured cost understates the real burden, and that finding is relevant to other non-endemic European countries.
Public-health planners should read the current zero as the present surveillance position. A zero records what has been detected so far. It does not measure the conditions that drive transmission. Any cost estimate that assumes the zero will hold all season should be read with that limit in mind.
What reduces risk now
European readers are not deploying soldiers. The measures that reduce dengue and chikungunya risk are well established, and they match the guidance from WHO and ECDC. Physical barriers come first:
- Wear long-sleeved clothing in the hours when Aedes mosquitoes are active, and use a treated or untreated mosquito net.
- Screen windows and doors so the mosquito cannot enter the rooms you use.
- Apply repellent according to the product label, and reapply it at the interval the label gives.
- Reduce standing water around the home: empty containers, clear gutters, and keep water stores covered.
For a permethrin-treated net, the relevant regulation is the European Biocidal Products Regulation. Treated products are not recommended for every population. Match the recommendation to the local label and to the needs of the person using it. A "natural" or "premium" label does not guarantee protection. The factors that decide performance are the active-ingredient concentration and the re-application interval.
A treated or untreated net, fitted correctly in a room with screened windows, continues to work as designed. Physical barriers do not depend on an active ingredient or on repeated application, and they remain in place across seasons.
What the Sri Lanka data is for
The Sri Lankan outbreak is not a forecast. It is a current picture of dengue transmission at scale. The conditions that sustain Aedes albopictus are present in Europe. The 2025 chikungunya outbreak in mainland France showed what those conditions can produce in a single warm season.
The IJID Regions paper records the cost of one arboviral season in metropolitan France. The household measures above reduce exposure wherever the vector is established. They do not depend on the case count in another country falling, and households can act on them now.
Sources
- The BMJ · Sri Lanka military deployed in dengue response as cases pass 55,000 · 2 July 2026 · https://doi.org/10.1136/bmj-2026-100152
- European Centre for Disease Prevention and Control · Dengue infection page · https://www.ecdc.europa.eu/en/dengue-fever
- European Centre for Disease Prevention and Control · Aedes albopictus factsheet · https://www.ecdc.europa.eu/en/disease-vectors/facts/mosquito-factsheets/aedes-albopictus
- Rozenberg B et al. From bites to ripple effects: Unraveling the health, economic, and social effects of arboviral epidemics in Mainland France. IJID Regions 2026, ahead of print (Sep). PMID 42382010.
Published 2026-07-03 · Mosticare Editorial
This article is general information, not medical advice. Ask a doctor or pharmacist about your own health.